ABIVAX SA
ABIVAX SA (AAVXF) Financial Performance & Income Statement Overview
Explore the financials of ABIVAX SA (AAVXF), including yearly and quarterly data on income, cash flow, and balance sheets.
ABIVAX SA (AAVXF) Income Statement & Financial Overview
Review ABIVAX SA AAVXF income statement with detailed quarterly and annual figures.
| Metric | Q2 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|
| Revenue | $6.79M | $1.12M | $1.12M | $1.12M |
| Cost of Revenue | $0.00 | $378000.00 | $0.00 | $329000.00 |
| Gross Profit | $6.79M | $744500.00 | $1.12M | $795000.00 |
| Gross Profit Ratio | $1.00 | $0.66 | $1.00 | $0.71 |
| R&D Expenses | $64.65M | $35.28M | $35.28M | $32.62M |
| SG&A Expenses | $22.16M | $10.95M | $10.95M | $6.58M |
| Operating Expenses | $86.78M | $46.17M | $47.80M | $39.21M |
| Total Costs & Expenses | $86.78M | $46.17M | $47.80M | $39.53M |
| Interest Income | $4.81M | $0.00 | $1.22M | $0.00 |
| Interest Expense | $7.89M | $5.70M | $0.00 | $14.70M |
| Depreciation & Amortization | $171000.00 | $65000.00 | $65000.00 | $329000.00 |
| EBITDA | -$79.83M | -$45.02M | -$45.02M | -$18.60M |
| EBITDA Ratio | -$11.76 | -$40.11 | -$40.11 | -$34.88 |
| Operating Income | -$80.00M | -$45.05M | -$45.09M | -$39.53M |
| Operating Income Ratio | -$11.79 | -$40.13 | -$40.17 | -$35.17 |
| Other Income/Expenses (Net) | -$4.31M | -$2.85M | -$2.85M | -$14.65M |
| Income Before Tax | -$84.30M | -$47.89M | -$47.89M | -$54.19M |
| Income Before Tax Ratio | -$12.42 | -$42.67 | -$42.67 | -$48.21 |
| Income Tax Expense | -$2.67M | -$2.26M | $0.00 | -$2.23M |
| Net Income | -$81.64M | -$47.89M | -$47.89M | -$51.95M |
| Net Income Ratio | -$12.03 | -$42.67 | -$42.67 | -$46.22 |
| EPS | -$1.30 | -$0.95 | -$0.95 | -$1.45 |
| Diluted EPS | -$1.30 | -$0.95 | -$0.95 | -$1.45 |
| Weighted Avg Shares Outstanding | $62.92M | $50.23M | $50.23M | $35.90M |
| Weighted Avg Shares Outstanding (Diluted) | $62.92M | $50.23M | $50.23M | $35.90M |
Financial performance has remained strong, with revenue growing from $1.12M in Q2 2023 to $6.79M in Q2 2024. Gross profit continued to perform well, with margins at 100% in the latest quarter. Operating income reached -$80.00M in Q2 2024, holding a steady -1179% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at -$79.83M. Net income dropped to -$81.64M, keeping EPS at -$1.30. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan